Eli Lilly and Company
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$32Mgeneral payments (2019-2025)
$116Mresearch payments (2019-2025)
8,544clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Ebglyss $991K associated (2023-2025)
- Olumiant $633K associated (2023-2025)
- Omvoh $627K associated (2023-2025)
- Taltz $568K associated (2023-2025)
- Kisunla $391K associated (2023-2025)
- Mounjaro $315K associated (2023-2025)
- Zepbound $206K associated (2023-2025)
- Jaypirca $151K associated (2023-2025)
- Jardiance $150K associated (2023-2025)
- Verzenio $130K associated (2023-2025)
- Retevmo $58K associated (2023-2025)
- Emgality $30K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Marschall Runge | Ann Arbor, MI | Cardiovascular Disease | $1,756,838.16 |
| Peter Marks | New Haven, CT | Medical Oncology | $577,600.00 |
| Milton Packer | Dallas, TX | Cardiovascular Disease | $489,917.06 |
| Bharathi Vennapusa | Tucson, AZ | Anatomic Pathology & Clinical Pathology | $347,587.50 |
| Kevin Winthrop | Portland, OR | Infectious Disease | $270,133.21 |
| Brett King | Fairfield, CT | Dermatology | $259,844.03 |
| James Stein | Madison, WI | Hypertension Specialist | $258,571.00 |
| Jonathan Silverberg | Washington, DC | Dermatology | $220,617.42 |
| Ann Navar | Dallas, TX | Cardiovascular Disease | $200,270.61 |
| David D Alessio | Durham, NC | Endocrinology, Diabetes & Metabolism | $186,822.71 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.